Closely-held Complexa appointed Francisco Salva as the company’s new CEO and president, effective immediately.
Mr. Salva will build on the company’s progress to date by further advancing the Phase 2 clinical development of its lead compound, CXA-10, in two orphan indications: pulmonary arterial hypertension and focal segmental glomerulosclerosis. He will also focus on the development of the next-generation of nitrated fatty acid compounds to support the growth of the company.
Most recently, Mr. Salva served as a founder and VP of operations for Acerta Pharma, where he focused on growth initiatives culminating in a $4-billion investment by AstraZeneca for a controlling ownership interest.
“We look forward to Francisco leading Complexa during this critical time in our growth as we advance our lead compound, CXA-10, in Phase 2 clinical development to help patients suffering from debilitating and life-threatening diseases,” David Mott, chairman, said in a statement.
Mr. Salva said he looks forward to joining the Complexa management team, initiating the Phase 2 clinical development of CXA-10 and finding solutions to transform the lives of patients suffering from fibrotic and inflammatory diseases.
